Home > Insider Trading > Filing (0001439222-24-000052)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc.	AGIO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1840056	Cecilia Jones	C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-03-01	2,000	$0.00	15,512	No	4	M	Direct
Common Stock	Disposition	2024-03-05	672	$32.57	14,840	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted stock units	Acquisiton	2024-03-01	17,000	$0.00	17,000	$0.00
Common Stock	Stock options (right to buy)	Acquisiton	2024-03-01	60,000	$0.00	60,000	$32.27
Common Stock	Restricted stock units	Disposition	2024-03-01	2,000	$0.00	2,000	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,000		No	4	A	Direct
60,000	2034-03-01	No	4	A	Direct
4,000		No	4	M	Direct

Footnotes

Includes 942 shares purchased through the Company's employee stock purchase plan.
Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter.
The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.